Merck KGaA, the German pharma giant, agreed on October 19 to acquire Silence Therapeutics for $20.00 per U.S.-listed share in cash. That values the U.K. biotech at about $1.3B in equity ($1.1B enterprise value), a 130% premium over Silence’s last closing price before the announcement.
The gap is easy to see in the share price. Silence closed at $8.70 on October 16, and its 30-day average was $10.99. Merck’s $20.00 offer is 82% above that average.
What Merck is buying
The prize is divesiran, a Phase 3-ready siRNA drug for phlebotomy-dependent polycythemia vera (PV), a rare blood cancer where the bone marrow overproduces red blood cells. Divesiran isn’t approved yet. Merck is buying a drug candidate rather than a product on shelves.
The case for it rests on strong Phase 2 results: 88% of patients responded, versus 19% on placebo. It is also dosed once every three months, compared with weekly injections for Takeda’s rival drug, Mimrylo.
The drug uses siRNA, which “silences” a gene’s message so the protein is never made, instead of blocking the protein afterward. Divesiran silences TMPRSS6, a liver gene that controls iron supply, and that limits how many red blood cells the bone marrow can make.
Why pay double
Merck doesn’t have a hematology business today. This deal gives it an entry point into a new disease area, plus Silence’s siRNA platform for future drugs, not just one product. Buying Silence is faster than building this drug internally, but it is not risk-free: divesiran still has to succeed in Phase 3.
This isn’t Merck’s first move like this, either. It bought SpringWorks Therapeutics in 2025, a $3.9B deal by equity value, using the same playbook. Large pharma companies increasingly prefer buying promising small biotechs over building new drugs in-house, since early research is expensive and failure-prone. For a small biotech, this is often the real payoff: not selling a finished drug, but getting acquired before the drug is even approved. A 130% premium is the acquirer’s way of saying it believes the drug is worth more than Silence could capture alone.
The takeaway
A drug doesn’t need FDA approval to be worth over a billion dollars; strong trial data and the right disease category are enough. Phase 2 data, not Phase 3, was enough to trigger this deal. Acquirers sometimes move before a company’s hardest clinical test is finished if the risk looks acceptable.
The price of a deal also tells you as much about the buyer’s strategy as it does about the drug itself. Watch the acquirer’s pattern, not just the target: Merck doing this twice in two years, with SpringWorks and now Silence, tells you more about its strategy than any single deal does.